Evommune Inc. Company Profile
NYSE: EVMNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Evommune at a glance
Evommune Inc. (NYSE: EVMN) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Palo Alto, CA. Evommune is led by Mr. Luis C. Pena and employs about 48 people. The company's shares have traded publicly since 2025.
At a market capitalization of $291.1 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0002044725, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Evommune do?
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
Business description based on the company's public filings.
Company information
- Legal name
- Evommune Inc.
- Ticker
- NYSE: EVMN
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Luis C. Pena
- Employees
- 48
- Headquarters
- 1891 Page Mill Road, Palo Alto, CA, United States
- Phone
- (925) 247-4481
- Website
- evommune.com
- IPO year
- 2025
- Market cap
- $291.10M
- SEC CIK
- 0002044725
Companies similar to Evommune
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BNTCBenitec Biopharma Inc. | 7.92 | -2.76% | $285.88M | vs EVMN |
| SPRYARS Pharmaceuticals Inc. | 2.96 | -11.90% | $297.56M | vs EVMN |
| GLSIGreenwich LifeSciences Inc. | 19.25 | -2.73% | $282.56M | vs EVMN |
| FULCFulcrum Therapeutics Inc. | 3.69 | -0.54% | $281.85M | vs EVMN |
| RLMDRelmada Therapeutics Inc. | 2.62 | -15.76% | $279.54M | vs EVMN |
| GALTGalectin Therapeutics Inc. | 2.69 | -4.27% | $271.35M | vs EVMN |
| VCREVicore Pharma Holding AB ADR | 9.41 | -5.09% | $264.89M | vs EVMN |
| AVIRAtea Pharmaceuticals Inc. | 3.96 | +0.76% | $318.00M | vs EVMN |